Bain Capital in Talks to Acquire PCI Pharma For $10 Billion

Bain Capital is in advanced discussions to acquire contract drug manufacturer PCI Pharma Services in a deal that would value the company at approximately $10 billion, Bloomberg News reported, according to Reuters.

The deal would mark one of the largest private equity transactions in the pharmaceutical services sector in recent years. I Photo: PR Newswire

The private equity firm is negotiating with PCI's current backers—Kohlberg & Co., Mubadala Investment Co., and Partners Group Holding AG—for a majority stake in the Philadelphia-based pharmaceutical services provider.

PCI specializes in “fill-finish” services, including the sterile filling and packaging of syringes and injection pens for pharmaceutical clients.

The company also supports drugmakers with tools and services that aid in the research and development of new treatments.

As part of the deal, Bain has reportedly approached a number of potential co-investors, including sovereign wealth funds, to help finance the equity portion of the transaction, sources familiar with the matter said.

The deal would mark one of the largest private equity transactions in the pharmaceutical services sector in recent years, underscoring continued investor interest in companies supporting drug development and manufacturing.